Latest Insider Transactions at Verastem, Inc. (VSTM)
This section provides a real-time view of insider transactions for Verastem, Inc. (VSTM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Verastem, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Verastem, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2022
|
Dan Paterson President and CEO |
SELL
Open market or private sale
|
Direct |
2,818
-0.59%
|
$2,818
$1.27 P/Share
|
|
Jan 31
2022
|
Brian M Stuglik Director |
SELL
Open market or private sale
|
Direct |
5,695
-0.5%
|
$5,695
$1.48 P/Share
|
|
Jan 03
2022
|
Dan Paterson President and CEO |
SELL
Open market or private sale
|
Direct |
23,534
-4.67%
|
$47,068
$2.05 P/Share
|
|
Jan 03
2022
|
Robert E. Gagnon Director |
SELL
Open market or private sale
|
Direct |
19,612
-3.39%
|
$39,224
$2.05 P/Share
|
|
Jan 03
2022
|
Brian M Stuglik Director |
SELL
Open market or private sale
|
Direct |
26,033
-2.23%
|
$52,066
$2.05 P/Share
|
|
Dec 20
2021
|
Robert E. Gagnon Director |
SELL
Open market or private sale
|
Direct |
5,497
-0.94%
|
$10,994
$2.27 P/Share
|
|
Dec 20
2021
|
Dan Paterson President and CEO |
SELL
Open market or private sale
|
Direct |
10,994
-2.13%
|
$21,988
$2.27 P/Share
|
|
Dec 20
2021
|
Brian M Stuglik Director |
SELL
Open market or private sale
|
Direct |
13,682
-1.16%
|
$27,364
$2.27 P/Share
|
|
Dec 15
2021
|
Brian M Stuglik Director |
BUY
Grant, award, or other acquisition
|
Direct |
363,000
+23.49%
|
-
|
|
Dec 15
2021
|
Robert E. Gagnon Director |
BUY
Grant, award, or other acquisition
|
Direct |
148,500
+20.26%
|
-
|
|
Dec 15
2021
|
Dan Paterson President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
181,500
+26.05%
|
-
|
|
Nov 01
2021
|
Brian M Stuglik Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,839
-0.71%
|
$11,678
$2.59 P/Share
|
|
Aug 12
2021
|
Robert E. Gagnon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
45,329
-9.42%
|
$90,658
$2.87 P/Share
|
|
Aug 12
2021
|
Dan Paterson President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
50,244
-13.08%
|
$100,488
$2.87 P/Share
|
|
Mar 25
2021
|
Brian M Stuglik Director |
BUY
Grant, award, or other acquisition
|
Direct |
191,828
+13.92%
|
-
|
|
Jan 06
2021
|
Frank Neumann Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+50.0%
|
-
|
|
Dec 18
2020
|
Dan Paterson President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
135,851
+19.64%
|
-
|
|
Dec 18
2020
|
Brian M Stuglik Director |
BUY
Grant, award, or other acquisition
|
Direct |
203,776
+17.01%
|
-
|
|
Dec 18
2020
|
Robert E. Gagnon Director |
BUY
Grant, award, or other acquisition
|
Direct |
67,925
+10.62%
|
-
|
|
Dec 04
2020
|
Timothy J Barberich Director |
BUY
Open market or private purchase
|
Direct |
50,000
+18.66%
|
$100,000
$2.17 P/Share
|
|
Jun 25
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,161,300
-6.71%
|
$1,161,300
$1.91 P/Share
|
|
Apr 27
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,301,300
-6.99%
|
$2,602,600
$2.31 P/Share
|
|
Mar 06
2020
|
Ridgeback Capital Investments L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
5,515,151
+35.39%
|
-
|
|
Sep 05
2017
|
Eric K Rowinsky Director |
BUY
Open market or private purchase
|
Indirect |
2,000
+50.0%
|
$6,000
$3.84 P/Share
|